Citas Apa

https://www.thelancet.com › pdfs › journals › lancet
Added value of this study To our knowledge EXCEED is the first fully blinded head to head trial to evaluate the eficacy and safety of secukinumab an IL 17A inhibitor versus adalimumab an anti

https://clinicaltrials.gov › study
Secukinumab versus adalimumab for treatment of active psoriatic arthritis EXCEED a double blind parallel group randomised active controlled phase 3b trial

https://www.novartis.com › news › media-releases › novartis-cosentyx...
EXCEED is the first double blinded head to head clinical trial evaluating Cosentyx secukinumab 300 mg versus Humira adalimumab 40 mg EXCEED is a 52 week multi center

https://academic.oup.com › bjd › article
EXCEED is the first double blind head to head study to evaluate the efficacy and safety of secukinumab vs adalimumab as a first line biological monotherapy in patients with active PsA who

https://ard.bmj.com › content
Background Secukinumab SEC an interleukin 17A inhibitor has demonstrated improvements on multiple domains of psoriatic arthritis PsA 1 Adalimumab ADA a TNF inhibitor is widely used as a

https://academic.oup.com › rheumatology › article
Methods Study design and patient data EXCEED was a multicentre randomized double blind active controlled parallel group phase 3 trial that evaluated the efficacy and safety of

https://pubmed.ncbi.nlm.nih.gov
Checking your browser before accessing pubmed ncbi nlm nih gov

https://www.sciencedirect.com › science › article › pii
Objectives To report efficacy and safety outcomes from the head to head EXCEED trial NCT02745080 that compares SEC vs ADA as first line biologic monotherapy through 52 weeks

https://digitalcommons.providence.org › publications
The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab as first line biological monotherapy for 52 weeks in patients with active psoriatic arthritis with a musculoskeletal